Publications

2017

Toonen JA, Solga AC, Ma Y, Gutmann DH. Estrogen activation of microglia underlies the sexually-dimorphic differences in Nf1 optic glioma-induced retinal pathology. J Exp Med 214:17-25, 2017.  PMID: 27923908

Hirbe AC, Kaushal M, Sharma MK, Dahiya S, Pekmezci M, Perry A, Gutmann DH. Clinical genomic profiling identifies TYK2 mutation and overexpression in neurofibromatosis type 1 (NF1) malignant peripheral nerve sheath tumors (MPNSTs). Cancer. doi:10.1002/cncr.30455. PMID: 27875628

Toonen JA, Ma Y, Gutmann DH. Defining the temporal course of murine Neurofibromatosis-1 optic gliomagenesis reveals a therapeutic window to attenuate retinal dysfunction. Neuro Oncol 2016 now267. doi: 10.1093/neuonc/now267. PMID: 28039362

Ricker CA, Pan Y, Gutmann DH, Keller C. Challenges in Drug Discovery for Neurofibromatosis Type-1 Associated Low-Grade Gliomas. Front Oncol. 2016; 6: 259. PMID: 28066715

2016

Anderson DM, Van de Plas R, Rose KL, Hill S, Schey KL, Solga AC, Gutmann DH, Caprioli RM. 3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma. J Proteomics. 2016 Feb 12. pii: S1874-3919(16)30027-6. doi: 10.1016/j.jprot.2016.02.004. [Epub ahead of print]

Chen YH, Cimino PJ, Luo J, Dahiya S, Gutmann DH. ABCG1 maintains high-grade glioma survival in vitro and in vivo. Oncotarget. 2016 Mar 10. doi: 10.18632/oncotarget.8030. [Epub ahead of print]

Hirbe AC, Dahiya S, Friedmann-Morvinski D, Verma IM, Clapp DW, Gutmann DH. Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formation. Oncotarget. 2016 Feb 7. doi: 10.18632/oncotarget.7232. [Epub ahead of print]

Hirbe AC, Kaushal M, Sharma MK, Dahiya S, Pekmezci M, Perry A, Gutmann DH. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Cancer. 2016 Nov 22. doi: 10.1002/cncr.30455. [Epub ahead of print]

Li K, Turner AN, Chen M, Brosius SN, Schoeb TR, Messiaen LM, Bedwell DM, Zinn KR, Anastasaki C, Gutmann DH, Korf BR, Kesterson RA. Mice with missense and nonsense NF1 mutations display divergent phenotypes compared with human neurofibromatosis type I. Dis Model Mech. 2016 Jul 1;9(7):759-67. doi: 10.1242/dmm.025783. Epub 2016 Jun 2.

Morris, SM, Acosta MR, Garg S, Green J, Huson S, Legius E, North KN, Payne JM, Plasschaert E, Frazier TW, Weiss LA, Zhang Y, Gutmann DH, Constantino JN, and the International NF1-ASD Consortium Team (INFACT). NF1 gene mutations engender the full spectrum of autism. JAMA Psychiatry. Oct. 19, 2016.

Morris SM, Monroe CL, Gutmann DH. Macrocephaly Is Not a Predictor of Optic Pathway Glioma Development or Treatment in Neurofibromatosis Type 1. Journal of Child Neurology. 2016 Aug 31. doi:10.1177/0883073816664659 [Epub ahead of print]

Schwetye KE, Joseph NM, Al-Kateb H, Rich KM, Schmidt RE, Perry A, Gutmann DH, Dahiya S. Gliosarcomas lack BRAFV600E mutation, but a subset exhibit β-catenin nuclear localization. Neuropathology. 2016 Mar 2. doi: 10.1111/neup.12293. [Epub ahead of print]

Smithson LJ, Anastasaki C, Chen R, Toonen JA, Williams SB, Gutmann DH. Contextual signaling in cancer. Semin Cell Dev Biol. 2016 Jun 3. pii: S1084-9521(16)30164-1. doi: 10.1016/j.semcdb.2016.06.002. [Epub ahead of print] Review.

Smithson LJ, Gutmann DH. Proteomic analysis reveals GIT1 as a novel mTOR complex component critical for mediating astrocyte survival. Genes Dev. 2016 Jun 15;30(12):1383-8. doi: 10.1101/gad.279661.116.

Toonen JA, Anastasaki C, Smithson LJ, Gianino SM, Li K, Kesterson RA, Gutmann DH. NF1 Germline Mutation Differentially Dictates Optic Glioma Formation and Growth in Neurofibromatosis-1. Hum Mol Genet. 2016 Feb 16. pii: ddw039. [Epub ahead of print]

Toonen JA, Ma Y, Gutmann DH. Defining the temporal course of murine neurofibromatosis-1 optic gliomagenesis reveals a therapeutic window to attenuate retinal dysfunction. Neuro Oncol. 2016 Dec 29. pii: now267. doi: 10.1093/neuonc/now267. [Epub ahead of print]

2015

Ackerman SD, Garcia C, Piao X, Gutmann DH, Monk KR. The adhesion GPCR Gpr56 regulates oligodendrocyte development via interactions with Gα12/13 and RhoA. Nat Commun. 6:6122, 2015.

Anastasaki C, Woo AS, Messiaen LM, Gutmann DH. Elucidating the impact of neurofibromatosis-1 germline mutations on neurofibromin function and dopamine-based learning. Hum Mol Genet. 2015; doi: 10.1093/hmg/ddv103.

Bender RH, Haigis KM, Gutmann DH. Activated K-Ras, but not H-Ras or N-Ras, regulates brain neural stem cell proliferation in a Raf/Rb-dependent manner. Stem Cells. 2015; doi: 10.1002/stem.1990.

Brossier NM, Gutmann DH. Improving outcomes for neurofibromatosis 1-associated brain tumors. Expert Rev Anticancer Ther. 15(4):415-23, 2015.

Chen YH, Gianino SM, Gutmann DH. Neurofibromatosis-1 regulation of neural stem cell proliferation and multilineage differentiation operates through distinct RAS effector pathways. Genes Dev. 2015; doi:10.1101/gad.261677.115.

Chen Y-H, McGowan LDA, Cimino PJ, Dahiya S, Leonard JR, Lee DY, Gutmann DH. Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. Cell Rep. 10(11):1899-912, 2015.

Epstein JA, Ingram DA Jr, Hirbe AC, Gutmann DH. A multidisciplinary approach in neurofibromatosis 1–author’s reply. Lancet Neurol. 14(1):30-1, 2015.

Gutmann DH. Microglia in the tumor microenvironment: taking their TOLL on glioma biology. Neuro Oncol. 17(2):171-3, 2015.

Hirbe AC, Dahiya S, Miller CA, Li T, Fulton RS, Zhang X, McDonald S, DeSchryver K, Duncavage EJ, Walrath J, Reilly KM, Abel HJ, Pekmezci M, Perry A, Ley TJ, Gutmann DH. Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma. Clin Cancer Research. 21(18):4201-11, 2015.

Kaul A, Toonen JA, Gianino SM, Gutmann DH. The impact of coexisting genetic mutations on murine optic glioma biology. Neuro Oncol. 17(5):670-7, 2015.

Rauen KA, Huson SM, Burkitt-Wright E, Evans DG, Farschtschi S, Ferner RE, Gutmann DH, Hanemann CO, Kerr B, Legius E, Parada LF, Patton M, Peltonen J, Ratner N, Riccardi VM, van der Vaart T, Vikkula M, Viskochil DH, Zenker M, Upadhyaya M. Recent developments in neurofibromatoses and RASopathies: management, diagnosis and current and future therapeutic avenues. Am J Med Genet A. 167A(1):1-10, 2015.

Sharkey EK, Zoellner NL, Abadin S, Gutmann DH, Johnson KJ. Validity of participant-reported diagnoses in an online patient registry: A report from the NF1 Patient Registry Initiative. Contemp Clin Trials. 40:212-7, 2015.

Solga AC, Pong WW, Kim KY, Cimino PJ, Toonen JA, Walker J, Wylie T, Magrini V, Griffith M, Griffith OL, Ly A, Ellisman MH, Mardis ER, Gutmann DH. RNA Sequencing of Tumor-Associated Microglia Reveals Ccl5 as a Stromal Chemokine Critical for Neurofibromatosis-1 Glioma Growth. Neoplasia. 17(10):776-88, 2015.

Solga AC, Pong WW, Walker J, Wylie T, Magrini V, Apicelli AJ, Griffith M, Griffith OL, Kohsaka S, Wu GF, Brody DL, Mardis ER, Gutmann DH. RNA-sequencing reveals oligodendrocyte and neuronal transcripts in microglia relevant to central nervous system disease. Glia. 63(4):531-48, 2015.

Warrington NM, Sun T, Luo J, McKinstry RC, Parkin PC, Ganzhorn S, Spoljaric D, Albers AC, Merkelson A, Stewart DR, Stevenson DA, Viskochil D, Druley TE, Forys JT, Reilly KM, Fisher MJ, Tabori U, Allen JC, Schiffman JD, Gutmann DH, Rubin JB. The cyclic AMP pathway is a sex-specific modifier of glioma risk in type 1 neurofibromatosis patients. Cancer Res. 75(1):16-21, 2015.

Weiss B, Widemann BC, Wolters P, Dombi E, Vinks A, Cantor A, Perentesis J, Schorry E, Ullrich N, Gutmann DH, Tonsgard J, Viskochil D, Korf B, Packer RJ, Fisher MJ. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol. 17(4):596-603, 2015.

2014 Selected Publications

Anastasaki C, Gutmann DH. Neuronal NF1/RAS regulation of cyclic AMP requires atypical PKC activation.Hum Mol Genet. 23(25):6712-21, 2014.

Dahiya S, Emnett RJ, Haydon DH, Leonard JR, Phillips JJ, Perry A, Gutmann DH. BRAF-V600E mutation in pediatric and adult glioblastoma. Neuro Oncol. 16:318-9, 2014.

Diggs-Andrews KA, Brown JA, Gianino SM, Rubin JB, Wozniak DF, Gutmann DH. Sex is a major determinant of neuronal dysfunction in neurofibromatosis type 1. Ann Neurol. 75:309-16, 2014.

Garcia C, Gutmann DH. Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner. PLoS One. 9:e97320, 2014.

Garcia C, Gutmann DH. Using the neurofibromatosis tumor predisposition syndromes to understand normal nervous system development. Scientifica (Cairo). 2014; doi:10.1155/2014/915725.

Gutmann DH. NF GEMMs Already! The Power and promise of mouse tumor models. Cancer Cell. 26(5):596-9, 2014.

Gutmann DH. The taxonomy of brain cancer stem cells: what’s in a name? Oncoscience. 1(3):241-7, 2014.

Hirbe AC, Pekmezci M, Dahiya S, Apicelli AJ, Van Tine BA, Perry A Gutmann DH. BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Neuro Oncol. 16:466-7, 2014.

Huang YC, Wei KC, Chang CN, Chen PY, Hsu PW, Chen CP, Lu CS, Wang HL, Gutmann DH, Yeh TH. Transglutaminase 2 expression is increased as a function of malignancy grade and negatively regulates cell growth in meningioma. PLoS One. 9(9):e108228, 2014.

Kaul A, Toonen JA, Cimino PJ, Gianino SM, Gutmann DH. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth. Neuro Oncol. doi: 10.1093/neuonc/nou329, 2014.

Liu Q, Zoellner N, Gutmann DH, Johnson KJ. Parental Age and Neurofibromatosis Type 1: a report from the NF1 Patient Registry Initiative. Fam Cancer. 2014; doi: 10.1007/s10689-014-9774-8.

Pekmezci M, Reuss DE, Hirbe AC, Dahiya S, Gutmann DH, von Deimling A, Horvai AE, Perry A. Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas.Mod Pathol. 10.1038/modpathol.2014.109, 2014.

Plotkin SR, Albers AC, Babovic-Vuksanovic D, Blakeley JO, Breakefield XO, Dunn CM, Evans DG, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Kalamarides M, McClatchey AI, Messiaen L, Morrison H, Parkinson DB, Stemmer-Rachamimov AO, Van Raamsdonk CD, Riccardi VM, Rosser T, Schindeler A, Smith MJ, Stevenson DA, Ullrich NJ, van der Vaart T, Weiss B, Widemann BC, Zhu Y, Bakker AC, Lloyd AC. Update from the 2013 International Neurofibromatosis Conference. Am J Med Genet A. 164a(12):2969-78, 2014.

Solga AC, Gianino SM, Gutmann DH. NG2 cells are not the cell of origin for murine neurofibromatosis-1 (Nf1) optic glioma. Oncogene. 33:289-99, 2014.

2013 Selected Publications

Diggs-Andrews KA, Tokua K, Izumi I, Zorumski CF, Wozniak DF, Gutmann DH. Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice. Ann Neurol. 73:309-15, 2013.

Gutmann DH, McLellan MD, Hussain I, Wallis JW, Fulton LL, Fulton RS, Magrini V, Demeter R, Wylie T, Kandoth C, Leonard JR, Guha A, Miller CA, Ding L, Mardis EM. Somatic Neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma. Genome Res. 23:431-9, 2013.

Kaul A, Chen Y-H, Emnett RJ, Gianino SM, Gutmann DH. Conditional KIAA1549:BRAF mice reveal brain region- and cell type-specific effects. Genesis. 51: 708-16, 2013.

O’Brien DE, Brenner DS, Gutmann DH, Gereaux RW. Assessment of pain and itch behavior in a mouse model of Neurofibromatosis type 1. J. Pain. 14: 628-37, 2013.

Pong WW, Higer SB, Gianino SM, Emnett RJ, Gutmann DH. Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation. Ann. Neurol. 73:303-8. 2013.

Pong WW, Walker J, Wylie T, Margrini V, Luo J, Emnett RJ, Choi J, Cooper ML, Griffith M, Griffith OL, Rubin JB, Fuller GN, Piwnica-Worms D, Feng X, Hambardzumyan D, Dipersio JF, Mardis ER, Gutmann DH. F11R is a novel monocyte prognostic biomarker for malignant glioma. PLoS ONE. 11: e77571, 2013.

Schulz A, Baader SL, Niwa-Kawakita M, Jung MJ, Bauer R, Garcia C, Zoch A, Schacke S, Schroder JM, Mautner V-F, Hanemann CO, Dun X-P, Parkinson DB, Weis J, Hagel C, Gutmann DH, Giovannini M, Morrison H. The role of merlin isoform 2 in neurofibromatosis type 2-associated polyneuropathy. Nat. Neurosci.16:426-33, 2013.

Wozniak DF, Dearborn JT, Conyers S, Yuede CM, Brown JA, Diggs-Andrews KA, Tokuda K, Izumi Y, Zorumski CF, Gutmann DH. Motivational disturbances and effects of L-dopa administration in neurofibromatosis-1 model mice. PLoS One. 8:e66024, 2013.

2012 Selected Publications

2011 Selected Publications

2010 – 2006 Selected Publications

Banerjee S, Byrd JN, Gianino SM, Harpstrite SE, Rodriguez FJ, Tuskan RG, Reilly KM, Piwnica-Worms DR, Gutmann DH. Neurofibromin controls cell growth by regulating STAT3 activity in vitro and in vivo.  Cancer Res 70:1356-66, 2010.

Brown JA, Gianino SM, Gutmann DH. Defective cyclic AMP generation underlies the sensitivity of central nervous system neurons to neurofibromatosis-1 heterozygosity.  J Neurosci 30:5579-89, 2010.

Lee DY, Yeh T-H, Emnett RJ, White CR, Gutmann DH. Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner.  Genes & Development 24:2317-29, 2010.

Brown JA, Emnett RJ, White C, Yuede C, Conyers S, O’Malley K, Wozniak DF, Gutmann DH. Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice.  Human Mol Genet. 19:4515-28, 2010.

Houshmandi SS, Emnett RJ, Giovannini M, Gutmann DH: The neurofibromatosis-2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner.  Mol Cell Biol. 29:1472-86, 2009.

Yeh T-H, Lee DY, Gianino SM, Gutmann DH: Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.  GLIA 57:1239-49, 2009.

Yu J, Deshmukh H, Gutmann RJ, Emnett RJ, Rodriguez FJ, Watson MA, Nagarajan R, Gutmann DH: Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. Neurology 73:1526-31, 2009.

Hegedus B, Banerjee D, Yeh T-H, Rothermich S, Perry A, Rubin JB, Garbow JR, Gutmann DH: Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. Cancer Res. 68:1520-8, 2008.

Hegedus B, Yeh T-H, Lee DY, Emnett RJ, Li J, Gutmann DH: Neurofibromin regulates somatic growth through the hypothalamic-pituitary axis. Hum Mol Genet. 17:2955-2966, 2008.

Daginakatte GC, Gianino SM, Zhao NW, Parsadanian AS, Gutmann DH: Increased JNK signaling in Neurofibromatosis-1 (Nf1) heterozygous microglia drives microglia activation and promotes optic glioma proliferation.  Cancer Res. 68:10358-10366, 2008.

Sharma MK, Mansur DB, Reifenberger G, Perry A, Leonard JR, Aldape KD, Albin MG, Emnett RJ, Loeser S, Watson MA, Nagarajan R, Gutmann DH:  Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin.  Cancer Res. 67:890-900, 2007.

Daginakatte GC, Gutmann DH:  Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth.  Hum Mol Genet. 16:1098-1112, 2007.

Sandsmark DK, Zhang H, Hegedus B, Pelletier CL, Weber JD, Gutmann DH: Nucleophosmin mediates mammalian target of rapamycin-dependent actin cytoskeleton dynamics and proliferation in neurofibromin-deficient astrocytes.  Cancer Res. 67:4790-9, 2007.

Hegedus B, Dasgupta B, Shin JE, Emnett RJ, Hart-Mahon EK, Elghazi L, Bernal-Mizrachi E, Gutmann DH: Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-dependent mechanisms.  Cell Stem Cell 1:443-457, 2007.

Sharma MK, Watson MA, Lyman M, Perry A, Aldape KD, Deak F, Gutmann DH: Matrilin-2 expression distinguishes clinically relevant subsets of pilocytic astrocytoma. Neurology 66:127-130, 2006.

Gerber MA, Bahr SM, Gutmann DH: Protein 4.1B/DAL-1 functions as a growth suppressor in meningioma cells by activating Rac1-dependent JNK signaling. Cancer Res. 66:5295-303, 2006.

2005 – 2000 Selected Publications

Bajenaru ML, Garbow JR, Perry A, Hernandez MR, Gutmann DH:  Natural history of neurofibromatosis 1-associated optic nerve glioma formation in mice.  Ann Neurol. 57:119-27, 2005.

Dasgupta B, Li W, Perry A, Gutmann DH: Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes.  Cancer Res. 65:236-45, 2005.

Robb VA, Gerber MA, Hart-Mahon EK, Gutmann DH: Membrane localization of the U2 domain of Protein 4.1B is necessary and sufficient for meningioma growth suppression.  Oncogene 24:1946-57, 2005.

Scheidenhelm DK, Cresswell J, Haipek CA, Fleming TP, Mercer RW, Gutmann DH:  Akt-dependent cell size regulation by the adhesion molecule on glia (AMOG) occurs independently of phosphotidylinositol 3-kinase and Rheb signaling.  Mol Cell Biol. 25:3151-62, 2005.

Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH:  Proteomic analysis reveals hyperactivation of the mTOR pathway in NF1-associated human and mouse brain tumors.  Cancer Res. 65:2755-60, 2005.

Dasgupta B, Gutmann DH: Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation in vitro and in vivo. J Neurosci. 25:5584-94, 2005.

Sharma MK, Zehnbauer BA, Watson MA, Gutmann DH: RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma. Neurology 65:1335-6, 2005.

Surace EI, Haipek CA, Gutmann DH:  The effect of merlin phosphorylation on neurofibromatosis 2 (NF2) gene function.  Oncogene 23: 580-7, 2004.

Surace EI, Lusis E, Haipek CA, Gutmann DH:  Functional significance of S6K overexpression in meningioma progression.  Ann Neurol. 56:295-98, 2004.

Huang Z-y, Wu Y, Burke SP, Gutmann DH: The 43-kDa growth associated protein functions as a negative growth regulator in glioma.  Cancer Res.  63:2933-2939, 2003.

Dasgupta B, Dugan LL, Gutmann DH:  The neurofibromatosis 1 gene product neurofibromin regulates Pituitary Adenylate Cyclase-Activating Polypeptide-mediated signaling in astrocytes.  J Neurosci. 23:8949-54, 2003.

Bajenaru ML, Hernandez MR, Perry A, Zhu Y, Parada LF, Garbow JR, Gutmann DH: Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity.  Cancer Res. 63: 8573-8577, 2003.

Gutmann DH, Hedrick NM, Li J, Nagarajan R, Perry A, Watson MA.  Comparative gene expression profile analysis of neurofibromatosis 1 (NF1)-associated and sporadic pilocytic astrocytomas.  Cancer Res.  62:2085-2091, 2002.

Kalamarides M, Niwa-Kawakita M, Leblois H, Abramowski V, Perricaudet M, Janin A, Thomas G,Gutmann DH, Giovannini M. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse.  Genes & Development 16:1060-1065, 2002.

Bajenaru ML, Zhu Y, Hedrick NM, Donahoe J, Parada LF, Gutmann DH.  Astrocyte-Specific Inactivation of the Neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation.  Mol Cell Biol. 22:5100-5113, 2002.

Uhlmann EJ, Wong M, Baldwin RL, Bajenaru ML, Onda H, Kwiatkowski DJ, Yamada K, Gutmann DH.  Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures.  Ann Neurol. 52:285-296, 2002.

Bajenaru ML, Donahoe J, Corral T, Reilly KM, Brophy S, Pellicer A, Gutmann DH: Neurofibromatosis 1 (NF1) Heterozygosity results in a cell-autonomous growth advantage for astrocytes.  GLIA 33:314-323, 2001.

Li J, Perry A, James CD, Gutmann DH: Cancer-related gene expression profiles in NF1-associated pilocytic astrocytomas.  Neurology 56:885-890, 2001.

Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, Gutmann DH, Ponta H, Herrlich P:  The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44.  Genes & Development 15:968-980, 2001.

Gutmann DH, Hirbe AC, Haipek CA:  Functional analysis of neurofibromatosis 2 (NF2) missense mutations.  Hum Mol Genet. 10:1519-1529, 2001.

Gutmann DH, Wu YL, Hedrick NM, Zhu Y, Guha A, Parada LF:  Heterozygosity for the neurofibromatosis 1 (NF1) tumor suppressor results in abnormalities in cell attachment, spreading and motility in astrocytes.  Hum Mol Genet. 10:3009-3016, 2001.

Gutmann DH, Donahoe J, Perry A, Lemke N, Gorse K, Kittiniyom K, Rempel SA, Gutierrez JA, Newsham IF:  Loss of DAL-1, a Protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas.  Hum Mol Genet. 9:1495-1500, 2000.

1999 – 1997 Selected Publications

Gutmann DH, Loehr A, Zhang Y, Kim J, Henkemeyer M and Cashen A:  Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation.  Oncogene 18:4450-4459, 1999.

Gutmann DH, Geist RT, Xu HM, Kim JS, and Saporito-Irwin S.  Defects in neurofibromatosis 2 protein function can arise at multiple levels.  Hum Mol Genet. 7:335-345, 1998.

Sherman L, Xu HM, Geist RT, Saporito-Irwin S, Howells N, Ponta H, Herrlich P and Gutmann DH:  Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene 15:2505-2509, 1997.